Materiality
Kyowa Kirin Group's Management Philosophy and CSV Management
The Group's management philosophy is "The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies." By "new value," we mean value that can be shared by society at large. In other words, we focus on "Creating Shared Value (CSV)." Our Group practices CSV management aimed at realizing enhanced corporate value through the creation of both social and economic value.
Our Vision
Under its management philosophy, Kyowa Kirin has set a vision for 2030: "Kyowa Kirin will realize the successful creation and delivery of life-changing value that ultimately makes people smile, as a Japan-based Global Specialty Pharmaceutical company built on the diverse team of experts with shared passion for innovation."
Materiality
Strategy, metrics and targets
The Kyowa Kirin Group has positioned materiality as a management challenge to realize our vision for 2030. Our identified materialities are categorized as 'value creation topics' and 'value enhancement topics' , which corresponds to the strategic pillars to realize our vision for 2030: "Provide pharmaceutical products for unmet medical needs", "Address patient-centric healthcare needs", "Retain the trust of society", and "Management infrastructure to realize Life-changing value".
You can see this table by scrolling horizontally.
| Strategic | Materiality | Definition |
|---|---|---|
|
Creation of innovative medicines | Continue to create innovative drugs that create and deliver Life-changing value through proactive investment in research (including open innovation activities) based on a medium- to long-term perspective, while maintaining an appropriate balance with short-term profitability |
| Maximization of product value | Maximize value by identifying the true value of created medicines, promoting life cycle management(LCM), and utilising partnering opportunities | |
| Pipeline enrichment | Based on portfolio analysis, enhance the pipeline around focus disease areas by leveraging increasing development efficiencies and partnering opportunities | |
|
Access to medicine | Commit to activities in accordance with Kyowa Kirin Group Policy for Access to Medicines (especially improved access to medicines), seeing it as our mission to listen to voice of people living with disease, create medicines that satisfy unmet medical needs, and deliver them to as many patients as possible, as quickly as possible |
| Co-creation of new value based on the needs of people facing illness | Focusing on disease areas where we concentrate our efforts, we listen sincerely to the voices of people facing illness, understand their true needs, and connect with stakeholders at various points in the value chain to co-create life-changing value | |
|
Talent portfolio | Develop an organizations and a portfolio of human resources that promote value creation with the aim of creating and delivering Life-changing value, and promote human resource management that leverages diversity (Diverse Perspectives and Differences in Core Values) to achieve this goal |
| Corporate culture | Foster a corporate culture of "KABEGOE" appropriate for J-GSP, toward the creation and delivery of Life-changing value | |
| Digital transformation | Accelerate the creation and delivery of Life-changing value and levarage of data obtained from various stakeholders including people facing illness, at various points in the value chain, from research and development to post-marketing |
Related SDGs
You can see this table by scrolling horizontally.
| Strategic | Materiality | Definition |
|---|---|---|
|
Product supply and quality assurance | Establish and appropriately operate a system and procedures to ensure the continued quality assurance and stable supply of products supplied by the company |
| Reduction of environmental impact | Proactively work to protect the global environment for future generations by considering environmental impacts at various points in the value chain | |
|
|
Corporate governance | Realize a corporate governance structure that enables us to promote sustainable growth and medium- to long-term corporate value enhancement with agility through the realization of our vision, based on our management philosophy and values |
| Ethics and transparency |
Comply with domestic and international laws and regulations, internal and external rules and regulations, and social norms, and act in a manner that fulfills our legal responsibilities and the ethical responsibilities demanded by society.In addition, encourage all partners that make up the value chain to act in accordance with the spirit of our Code of Conduct and co-create value. Also, disclose information to stakeholders in a proper, appropriate, and fair manner
|
|
| Reinforce risk management | Take appropriate risks necessary and take actions to protect the Kyowa Kirin Group and its stakeholders from threats |
Related SDGs
Governance
In 2021, we identified our materiality from the viewpoints of the impact on social sustainability and the impact on the Group’s business, taking into account stakeholder dialogue.
Since then, the materiality has been incorporated into and promoted through the FY2021–2025 Medium-Term Management Plan and the linked annual business plans.
From 2026 onward, the materiality will be aligned with “Vision 2030 and Beyond” and incorporated into annual business plans. Progress is monitored on a quarterly basis and reported to the Global Executive Committee and the Board of Directors. To promote the resolution of medium- to long-term management issues, performance indicators from 2024 include the degree of achievement of non-financial targets, including those related to materiality, set forth in the annual business plans.
The materiality is reviewed annually in light of changes in the internal and external environment. Any revisions are reviewed and approved by the Global Executive Committee and the Board of Directors.
Identification/Implementation Process of Materiality
